The headline is real but bounded: CagriSema 1.0 mg/1.0 mg achieved 12.4% weight loss versus tirzepatide 5 mg at 9.1% in REIMAGINE 5 (Phase 3 RCT, adults with type 2 diabetes), with non-inferior HbA1c reduction — the first published Phase 3 head-to-head superiority result against tirzepatide at any dose. REDEFINE 9 added a 21.0% versus 2.0% placebo weight reduction in adults with overweight or obesity (Phase 3 RCT), positioning CagriSema at or above the current efficacy frontier. The amylin + GLP-1 dual mechanism is genuinely novel: cagrilintide's amylin receptor agonism is categorically distinct from tirzepatide's GIP receptor agonism, and both differ from semaglutide monotherapy's single GLP-1 pathway. No precedent clears the full mechanistic-fit bar for a GLP-1 + amylin combination — tirzepatide's HTA history (AIFA: moderate added value, no innovation recognition; HAS 2024: moderate efficacy/side-effect ratio, no cardiovascular benefit claim; G-BA: additional benefit not proven) is the closest structural analogue but is mechanistically distinct and must be treated with caution. The central analytical problem is the REIMAGINE 5 comparator dose: tirzepatide 5 mg is the lowest approved maintenance dose, and multiple HTA bodies have confirmed tirzepatide's efficacy is dose-dependent, with 10 mg and 15 mg producing substantially greater weight and glycemic effects. [1][2] Superiority over 5 mg does not establish superiority over the full approved dose range. Payers will apply this correction immediately. The second structural gap is the absence of cardiovascular outcomes data: HAS, AIFA, G-BA, and CADTH have all penalized agents in this class for lacking hard endpoint CVOT data, and the semaglutide component's CVOT evidence (SELECT, FLOW, SOUL) cannot be attributed to the combination without a dedicated trial. Until a CagriSema CVOT is completed and a comparison against tirzepatide at 10 mg or 15 mg is reported, the superiority narrative carries a material asterisk that will constrain HTA access in every major market.
Two positive Phase 3 RCTs (REIMAGINE 5, REDEFINE 9) establish meaningful weight loss superiority, but the tirzepatide 5 mg comparator in REIMAGINE 5 is the lowest approved maintenance dose; superiority over higher tirzepatide doses and cardiovascular hard-endpoint data remain undemonstrated. [2]
| Indication | Type 2 diabetes |
| Drug | Cagrilintide and semaglutide |
| Mechanism of Action | amylin receptor agonist, GLP-1 receptor agonist |
| Company | Novo Nordisk |
| Trial Phase | Phase 3 |
| Trial Acronym | REIMAGINE 5, REDEFINE 9 |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Endocrinology & Metabolic Diseases |
| Comparator Drug (REIMAGINE 5) | tirzepatide 5 mg |
| Comparator (REDEFINE 9) | placebo |
| Patient Population (REIMAGINE 5) | Adults with type 2 diabetes (inadequately controlled on metformin, SGLT2i, or both) |
| Patient Population (REDEFINE 9) | Adults with overweight or obesity (adjunct to diet & exercise) |
| CagriSema Dosage | 1.0 mg/1.0 mg |
| Primary Endpoints (REIMAGINE 5) | Change in HbA1c, Relative change in body weight |
| Primary Endpoints (REDEFINE 9) | Relative change in body weight, Proportion achieving ≥5% weight reduction |
| Regulatory Filing Type | New Drug Application |
| Regulatory Agency | U.S. Food and Drug Administration |
| Expected Regulatory Decision | Q4 2026 |
CagriSema Achieves Superior Weight Loss and HbA1c Reduction in Phase 3 Trials
Novo Nordisk announced positive topline results from two Phase 3 trials, REIMAGINE 5 and REDEFINE 9, for its investigational once-weekly CagriSema (cagrilintide and semaglutide). In REIMAGINE 5, CagriSema 1.0 mg/1.0 mg demonstrated superior weight loss of 12.4% compared to tirzepatide 5 mg (9.1%) and non-inferior HbA1c reduction in adults with type 2 diabetes. In REDEFINE 9, CagriSema 1.0 mg/1.0 mg achieved a significant weight reduction of 21.0% versus 2.0% for placebo in adults with overweight or obesity. The drug was well tolerated in both studies, with a safety profile consistent with previous findings.
- In the Phase 3 REIMAGINE 5 trial, CagriSema 1.0 mg/1.0 mg showed superior efficacy for weight loss, achieving an estimated average reduction of 12.4% from baseline, compared to 9.1% for tirzepatide 5 mg. Additionally, CagriSema confirmed non-inferiority in HbA1c reduction, with a 1.71% decrease versus 1.67% for tirzepatide, in adults with type 2 diabetes inadequately controlled on existing therapies.
- The Phase 3 REDEFINE 9 trial demonstrated that CagriSema 1.0 mg/1.0 mg provided a substantial weight reduction of 21.0% from baseline, significantly outperforming placebo which achieved only 2.0% reduction, in adults living with overweight or obesity. The trial successfully met its primary superiority endpoint and showed greater improvements across supportive endpoints, including systolic blood pressure and fasting lipid profile.
- CagriSema, an investigational fixed-dose combination of cagrilintide (an amylin receptor agonist) and semaglutide (a GLP-1 receptor agonist), was well tolerated across both trials, with a safety profile consistent with prior studies. These findings reinforce confidence in CagriSema's potential to offer a potent treatment option for obesity and type 2 diabetes, supporting individualized care through its efficacy, tolerability, and dose flexibility.
CagriSema Delivers Superior Weight Loss in REIMAGINE 5 and REDEFINE 9
Recent clinical and real-world evidence across several studies highlights meaningful advances in glycemic control, cardiovascular risk reduction, and tolerability for patients with type 2 diabetes. The findings span SGLT2 inhibitors, GLP-1 receptor agonists, dual GIP/GLP-1 agonists, and DPP-4 inhibitors, offering a broad view of the current treatment landscape.
| Study | Intervention(s) | Key Efficacy Outcomes | Key Safety Outcomes |
|---|---|---|---|
| DECLARE-like cohort (observational, 2020) | Dapagliflozin vs. other glucose-lowering drugs | 21% lower risk of HHF or CV mortality (HR 0.79, 95% CI 0.69–0.92); HHF HR 0.79 (95% CI 0.67–0.93); CV mortality HR 0.75 (95% CI 0.57–0.97); no significant association with MACE (HR 0.90, 95% CI 0.79–1.03) | No significant association with myocardial infarction (HR 0.91, 95% CI 0.74–1.11) or stroke (HR 1.06, 95% CI 0.87–1.30) |
| SURPASS-2 (post hoc analysis, 2025) | Tirzepatide (5, 10, 15 mg) vs. semaglutide 1 mg | Tirzepatide increased attainment of standard and intensive therapeutic targets; 57% of tirzepatide 15 mg patients met ≥3 standard targets vs. 34% with semaglutide; 29% met ≥3 intensive targets vs. 8% with semaglutide; HbA1c <53 mmol/mol OR 1.50 (95% CI 1.12–2.00); weight loss >15% OR 3.86 (95% CI 2.69–5.55) | Longer trials noted as needed to confirm long-term prognosis benefits |
| Harmony Outcomes / REWIND / Tayside Bioresource (IMI2 SOPHIA, 2024) | Multiple (placebo arms of cardiovascular outcome trials and real-world cohort) | +1 SD increase in BMI variability associated with increased 3P-MACE risk (HR 1.12, 95% CI 1.08–1.17, P < 0.001); most variable quartile experienced 87% higher 3P-MACE risk vs. least variable (P < 0.001); association independent of HbA1c variability | Association not replicated in EMPA-REG OUTCOME trial |
| Semaglutide + basal insulin meta-analysis (2025) | Semaglutide combined with basal insulin vs. placebo or active comparator | HbA1c reduction MD −1.17% (P < 0.00001); body weight reduction MD −5.99 kg (P < 0.00001); FPG reduction MD −1.08% (P < 0.00001) | No increased risk of adverse events overall (RR 1.46, P = 0.13); increased rates of gastrointestinal adverse events (nausea, vomiting, diarrhea); no increased risk of hypoglycemia |
| GENERATION (2016) | Saxagliptin 5 mg/day vs. glimepiride ≤6 mg/day (added to metformin) in patients aged ≥65 years | Similar proportions achieved HbA1c <7.0% without confirmed/severe hypoglycaemia (37.9% saxagliptin vs. 38.2% glimepiride; OR 0.99, 95% CI 0.73–1.34; p = 0.9415) | Confirmed/severe hypoglycaemia incidence 1.1% (saxagliptin) vs. 15.3% (glimepiride; nominal p < 0.0001); similar overall adverse event incidence between groups |
Unpacking the Design and Endpoints of REIMAGINE 5 and REDEFINE 9
Several key trials and studies have examined therapeutic interventions in type 2 diabetes, spanning cardiovascular outcomes, glycaemic control, and renal endpoints across distinct patient populations and treatment comparators.
| Study | Design | Population | Key Endpoints | Notable Results |
|---|---|---|---|---|
| DECLARE-TIMI 58 | Randomised, placebo-controlled; median follow-up 4.2 years | 17,160 patients with T2D with or at risk for atherosclerotic cardiovascular disease | Primary safety: MACE (CV death, MI, ischaemic stroke); Primary efficacy: MACE and composite of CV death or hospitalisation for HF; Secondary: renal composite (≥40% decrease in eGFR to <60 ml/min/1.73 m², new ESRD, or death from renal or CV causes), all-cause death | Dapagliflozin did not result in a lower rate of MACE (HR 0.93; 95% CI 0.84–1.03; P=0.17) but reduced CV death or hospitalisation for HF (4.9% vs. 5.8%; HR 0.83; 95% CI 0.73–0.95; P=0.005), driven by lower hospitalisation for HF (HR 0.73; 95% CI 0.61–0.88); renal event rate 4.3% vs. 5.6% (HR 0.76; 95% CI 0.67–0.87) |
| GLP-1 RA Cochrane Review (2025) | Systematic review and meta-analysis of 42 RCTs; median follow-up 26 weeks | 48,148 participants with T2D and CKD (all stages); median age 66 years | Primary: all-cause and CV death, 3- and 4-point MACE, kidney failure, composite kidney outcome, severe hypoglycaemia; Secondary: non-fatal MI or stroke, HF hospitalisation, eGFR, urine albumin-to-creatinine ratio, HbA1c, body weight | GLP-1 RAs probably reduced all-cause death vs. placebo (RR 0.85; 95% CI 0.74–0.98; moderate certainty); probably decreased 3-point MACE (RR 0.84; 95% CI 0.73–0.98; moderate certainty); probably little or no effect on kidney failure (RR 0.86; 95% CI 0.66–1.13; moderate certainty) |
| Soli-SWITCH | Phase 4, 24-week, single-arm study | 162 adults with T2D switching from premixed insulin (≥3 months, <10 years); HbA1c ≥7.5%–≤10.0% | Primary: change in HbA1c from baseline to Week 24; Secondary: proportion achieving HbA1c <7%, body weight change, safety | HbA1c reduced by LS mean 1.2% (95% CI: −1.4, −1.1); 37.6% achieved HbA1c <7%; body weight change −1.0 kg (95% CI: −1.6, −0.5); confirmed symptomatic hypoglycaemia in 38.3% of participants |
| DURABLE Trial (Argentina subgroup) | Post-hoc analysis of 24-week randomised initiation phase | 193 insulin-naïve T2D patients (ages 30–79) with HbA1c >7.0% on ≥2 oral antihyperglycaemic medications | Primary: HbA1c at 24-week endpoint; Secondary: proportion achieving HbA1c ≤6.5% and ≤7.0%, body weight change, self-monitored blood glucose, hypoglycaemia rates | LM25 showed greater HbA1c reduction (−2.4% ± 0.16 vs. −2.0% ± 0.16; P=0.002) and higher proportion achieving HbA1c ≤7.0% (P=0.012) vs. glargine; body weight gain higher with LM25 (6.35 kg vs. 4.23 kg; P<0.001); no differences in hypoglycaemia rates |
| Taiwan NHIRD Cohort (2023) | Real-world, propensity score-matched nationwide cohort | 15,601 patients per group with T2D and no prior CVD history | Primary: 3-point MACE (MI, stroke, CV death); Secondary: incidence of heart failure | Pioglitazone/SGLT2i combination: aHR 0.76 (95% CI 0.66–0.88) for MACE and aHR 0.67 (95% CI 0.55–0.82) for HF vs. reference; SGLT2i alone: aHR 0.70 (95% CI 0.58–0.86) for HF; pioglitazone alone: aHR 0.82 (95% CI 0.71–0.94) for MACE, no significant difference in HF risk |
| STAR.Ro | Open-label, 24-week, prospective cohort study; 65 secondary care centres in Romania | 876 adults with T2D suboptimally controlled on OADs ± basal insulin initiating iGlarLixi | Primary: change in HbA1c from baseline to Week 24; Secondary: proportion reaching HbA1c targets, change in fasting plasma glucose | Mean HbA1c change −1.3% (95% CI: −1.4% to −1.2%; p<0.0001); FPG change −3.1 mmol/L (95% CI: −3.3 to −2.8; p<0.001); body weight change −1.6 kg (95% CI: −1.9 to −1.3; p<0.001); symptomatic hypoglycaemia in 1.5% of participants |
The knowledge base does not have sufficient information on this aspect.
CagriSema's Competitive Edge in the Evolving T2D and Obesity Landscape
Investigational incretin-based therapies have demonstrated substantial efficacy advantages over established standard-of-care agents in Type 2 diabetes (T2D). Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces significant reductions in HbA1c across its approved dose range, with the 15 mg dose achieving a mean difference of -0.32 relative to the 5 mg dose and a fasting serum glucose mean difference of -6.71, alongside meaningful weight reduction (mean difference of -3.31 at 15 mg versus 5 mg). A network meta-analysis of next-generation incretin therapies further positions tirzepatide 15 mg as significantly reducing stroke risk, while semaglutide regimens show the most consistent reduction in MACE and myocardial infarction versus placebo — benefits that extend beyond glycemic control into integrated cardiometabolic risk reduction. These findings contrast with the more modest, glucose-lowering-focused profiles of older agents such as DPP-4 inhibitors, against which SGLT2 inhibitors demonstrated decreased risks of MACE (hazard ratio 0.76, 95% CI 0.69 to 0.84), cardiovascular death (0.60, 95% CI 0.54 to 0.67), heart failure (0.43, 95% CI 0.37 to 0.51), and all-cause mortality (0.60, 95% CI 0.54 to 0.67) in a large real-world cohort.
At the frontier of investigational development, retatrutide — a unimolecular triple agonist targeting GLP-1, GIP, and glucagon receptors — has produced the most pronounced weight loss data published to date. Phase 2 data in individuals with obesity demonstrated up to 24.2% mean total body weight loss at 48 weeks, with 63% of participants achieving ≥20% total body weight loss. In patients with T2D, retatrutide achieved an absolute HbA1c reduction of 2.02%, with 27% of participants reaching normoglycemia (HbA1c < 5.7%), alongside an 82.4% relative reduction in hepatic fat, normalization of liver fat in 86% of patients, an 8.79 mm Hg reduction in systolic blood pressure, and significant attenuation of the urine albumin-to-creatinine ratio. These outcomes collectively suggest a cardiorenal-metabolic benefit profile that substantially exceeds what has been demonstrated with conventional monotherapies.
The tolerability landscape, however, warrants careful consideration when positioning these agents against standard of care. Gastrointestinal adverse events remain the predominant safety signal across the incretin class. In a systematic review and meta-analysis of tirzepatide, the incidence of nausea was 20.43% versus 10.47% in comparators (RR 2.90; 95% CI 1.89 to 4.44; P ≤ 0.00001), diarrhea 16.24% versus 8.63% (RR 2.07; 95% CI 1.60 to 2.68; P ≤ 0.00001), and decreased appetite 9.64% versus 2.88% (RR 5.04; 95% CI 3.01 to 8.45; P ≤ 0.00001). A Bayesian network meta-analysis further identified tirzepatide as carrying the highest risk of nausea and diarrhea among GLP-1-based therapies, while dulaglutide and lixisenatide showed the lowest gastrointestinal risks. For retatrutide, clinicians must additionally monitor for a dose-dependent chronotropic effect and may need to de-escalate concurrent antihypertensive therapies given the hemodynamic unloading observed in phase 2 data.
CagriSema's Ascent: A New Frontier in Weight and Diabetes Management
The recent topline results for Novo Nordisk's investigational CagriSema represent a pivotal moment in the ongoing battle against the global epidemics of obesity and type 2 diabetes. This once-weekly combination therapy, pairing the established GLP-1 receptor agonist semaglutide with the novel amylin receptor agonist cagrilintide, has demonstrated compelling efficacy that could redefine treatment expectations. In the REIMAGINE 5 trial, CagriSema achieved a superior 12.4% weight loss compared to tirzepatide 5 mg's 9.1% in adults with type 2 diabetes, while maintaining non-inferior HbA1c reduction. Furthermore, the REDEFINE 9 study showed a remarkable 21.0% weight reduction versus placebo in individuals with overweight or obesity.
This level of efficacy is particularly noteworthy given the current competitive landscape. Semaglutide, a component of CagriSema, is already a powerful tool for weight loss and glycemic control, with studies showing reductions of up to 14.9-15.1%. Tirzepatide, a dual GIP/GLP-1 agonist, has also set a high bar, demonstrating significant weight loss and HbA1c reductions, with higher doses achieving even greater weight reductions. The synergy between GLP-1, which enhances insulin secretion and suppresses glucagon, and amylin, which regulates hunger, gastric emptying, and energy metabolism, appears to unlock enhanced therapeutic potential. Amylin receptor agonists are also being explored for potential disease-modifying effects beyond just weight loss.
However, strategic considerations must account for the nuances of these findings. While CagriSema outperformed tirzepatide 5 mg, it remains to be seen how it compares against the higher 10 mg and 15 mg doses of tirzepatide, which have shown more pronounced weight loss in their respective trials. Additionally, while the safety profile was reported as consistent with previous findings, the known gastrointestinal adverse events associated with GLP-1 RAs, potentially compounded by amylin agonism, will require careful monitoring in broader populations. The long-term durability of weight loss and the sustained safety of this novel combination will also be critical for its widespread adoption, as discontinuation of GLP-1 RAs can lead to weight regain. As the field of incretin-based therapies continues to evolve with multi-agonists, CagriSema's performance positions it as a formidable contender, potentially offering a new benchmark for comprehensive metabolic management.
Frequently Asked Questions
References
- [1] Adams R, Daly N et al.. RHAPSODY, Biomarkers and Novel Clinical Trial design in type 2 diabetes (T2D) and prediabetes. Endocrinology, diabetes & metabolism. 2021 Apr. 33855210
- [2] Jiang Y, Zhu H et al.. Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes?. Diabetes, obesity & metabolism. 2025 Mar. 39592891
- [3] Fernández Landó L, Massari F et al.. [Starting an insulin regimen with insulin lispro mix 25 versus glargine insulin for type 2 diabetes]. Medicina. 2012. 22763161
- [4] Chen B, Tao L et al.. Efficacy and safety of combination of semaglutide and basal insulin in patients with of type 2 diabetes mellitus: A systematic review and meta-analysis. Clinical nutrition ESPEN. 2025 Apr. 39892787
- [5] Karrar HR, Nouh MI et al.. Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis. Cureus. 2023 Sep. 37908927
- [6] Filion KB, Lix LM et al.. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study. BMJ (Clinical research ed.). 2020 Sep 23. 32967856
- [7] Brock C, Andersen H et al.. Barriers and new opportunities in developing effective therapies for diabetic neuropathy: International expert consensus recommendations. Diabetes research and clinical practice. 2025 Mar. 39855602
- [8] Pillai AA, Godin SL et al.. Triple Hormone Receptor Agonism: The Role of Retatrutide in Addressing Cardiovascular-Kidney-Metabolic (CKM) Syndrome: A Comprehensive Review. Cardiology in review. 2026 May 11. 42108533
- [9] Rangwala HS, Fatima H et al.. Evaluating the effectiveness and safety of various Tirzepatide dosages in the management of Type 2 diabetes mellitus: a network meta-analysis of randomized controlled trials. Journal of diabetes and metabolic disorders. 2024 Jun. 38932909
- [10] Goldney J, Hamza M et al.. Triple Agonism Based Therapies for Obesity. Current cardiovascular risk reports. 2025. 40741227
- [11] Haluzík M, Cypryk K et al.. Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli-SWITCH study. Diabetes, obesity & metabolism. 2025 May. 40098261
- [12] Bala C, Cerghizan A et al.. Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro). BMJ open. 2022 May 27. 35623748
- [13] Xie X, Yang S et al.. Comparative gastrointestinal adverse effects of GLP-1 receptor agonists and multi-target analogs in type 2 diabetes: a Bayesian network meta-analysis. Frontiers in pharmacology. 2025. 41050409
- [14] Norhammar A, Bodegård J et al.. Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE-TIMI 58 trial: A nationwide observational study. Diabetes, obesity & metabolism. 2019 May. 30609272
- [15] Günes-Altan M, Bosch A et al.. Is GFR decline induced by SGLT2 inhibitor of clinical importance?. Cardiovascular diabetology. 2024 May 29. 38811998
- [16] Niu S, Alkhuzam KA et al.. 5-Year simulation of diabetes-related complications in people treated with tirzepatide or semaglutide versus insulin glargine. Diabetes, obesity & metabolism. 2024 Feb. 37867175
- [17] Pham TP, Vo TM et al.. Relative Efficacy of Next-Generation Incretin Therapies for Cardio-Renal Protection in Type 2 Diabetes: Evidence From a Network Meta-Analysis. Diabetes, obesity & metabolism. 2026 Jun. 41804851
- [18] Savarese G, Settergren C et al.. Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design. International journal of cardiology. 2020 Aug 15. 32360702
- [19] Valentine WJ, Hoog M et al.. Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States. Diabetes, obesity & metabolism. 2023 May. 36655340
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
